BillionToOne reported third quarter 2026 financial results that exceeded analyst expectations on both the top and bottom lines, driven by significant volume expansion and pricing improvements. Following the strong performance, management raised its full-year 2026 revenue outlook to a range of $460 million to $470 million.
Key Highlights
- Total revenue reached $123.0 million, a 47% year-over-year increase that surpassed the $116.27 million consensus estimate.
- GAAP diluted EPS of $0.32 doubled the $0.16 estimate, supported by a 9% operating margin and $11.0 million in income from operations.
- Oncology testing revenue grew 96% year-over-year to $17.1 million, demonstrating continued rapid scale in the liquid biopsy portfolio.
- The company delivered 206,000 tests during the quarter, a 25% increase, while overall Average Selling Price (ASP) improved 18% to $589.